Modulation of oral bioavailability of anticancer drugs: from mouse to man

Jan H.M. Schellens(Utrecht University), Jos H. Beijnen(The Netherlands Cancer Institute), Olaf van Tellingen(Dutch Cancer Society), Mirte M. Malingré(Meander Medisch Centrum), C.M.F. Kruijtzer(The Netherlands Cancer Institute), Alfred H. Schinkel(Oncode Institute), Heleen A. Bardelmeijer(Slotervaartziekenhuis)
European Journal of Pharmaceutical Sciences
December 1, 2000
10.1016/s0928-0987(00)00153-6
Cited by 148

Related Papers

Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs
|Cell|1994|2.3k
Encorafenib, Binimetinib, and Cetuximab in <i>BRAF</i> V600E–Mutated Colorectal Cancer
|New England Journal of Medicine|2019|1.5k
Overcoming the blood–brain tumor barrier for effective glioblastoma treatment
|Drug Resistance Updates|2015|1k
Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins
|Proceedings of the National Academy of Sciences|1997|941
Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine
|Proceedings of the National Academy of Sciences|1997|884